Avances en el desarrollo de una vacuna efectiva contra Cryptosporidium parvum: una revisión de la literatura / Advances in the development of an effective vaccine against Cryptosporidium parvum: An review of the literature / Avanços no desenvolvimento de uma vacina eficaz contra Cryptosporidium parvum: uma revisão da literatura

Introducción. Cryptosporidium parvum es un parásito zoonótico altamente prevalente, asociado a enfermedad diarreica en población inmunocomprometida, niños y terneros menores de 30 días. Esta infección puede ocasionar deshidratación, alteración del estado de conciencia, retraso en el desarrollo global y, en algunos casos, la muerte del paciente. A pesar de la alta prevalencia de C. parvum, no existen medicamentos completamente efectivos ni una vacuna aprobada para prevenir dicha enfermedad. Objetivo. Realizar una revisión de la literatura sobre candidatos vacunales contra C. parvum. Método. Revisión documental mediante la búsqueda de la literatura de los últimos 20 años, disponible en las bases de datos PubMed central, WEB OF SCIENCE, Embase, REDALYC y LILACS. Resultados. Las vacunas atenuadas, recombinantes, basadas en ADN, expresadas en vectores bacterianos y sintéticas han mostrado resultados prometedores en la inducción de inmunogenicidad contra los antígenos de C. parvum, siendo el antígeno de superficie de 15 kilodaltons de Cryptosporidium parvum (cp15), el antígeno inductor de una mejor respuesta inmune celular y humoral en el modelo murino estudiado. Conclusión. Se espera que la incorporación de nuevas técnicas para la selección de antígenos promisorios y la ejecución de una gran cantidad de ensayos in vivo, favorezcan el desarrollo de una vacuna totalmente efectiva contra C. parvum. Aunque el camino para lograr este objetivo será largo y difícil, se convierte en la mejor alternativa para controlar una de las enfermedades de interés en salud pública, con mayor impacto en la población inmunocomprometida.

Introduction. Cryptosporidium parvum is a highly prevalent zoonotic parasite, associated with diarrheal disease in immunocompromised population, children and calves under 30 days. This infection is associa- ted to dehydration, delayed global development and, in some cases, the death of the patient. Despite the high prevalence of C. parvum, there are no fully effective medications and an approved vaccine to prevent such disease. Objective. To conduct a thorough review of the literature on vaccine candidates against C. parvum. Method Documentary review by searching the literature of the last 20 years, available in the central PubMed, WEB OF SCIENCE, Embase, REDALYC and LILACS databases. Results. Attenuated, recombinant, DNA-based, expressed in bacterial vectors and synthetic vaccines have shown promising results in inducing immunogenicity against C. parvum, being the Cryptospori- dium parvum 15 kiloDalton surface antigen (cp15), the antigen inducer of a better cellular and humoral immune response in the murine model studied. Conclusion. It is expected that the incorporation of new techniques for the selection of promising antigens and the execution of a large number of in vivo assays will favor the development of a fully effective vaccine against C. parvum. Although the way to achieve this goal will be long and difficult, it will become the best alternative to control one of the diseases with the greatest impact on the immu- nocompromised population.

Introdução. O Cryptosporidium parvum é um parasita zoonótico de alta prevalência associado à doença diarreica em populações imunocomprometidas, crianças e bezerros com menos de 30 dias. Essa infecção pode causar desidratação, alteração do estado de consciência, atraso no desenvolvi- mento global e, em alguns casos, a morte do paciente. Apesar da alta prevalência de C. parvum, não existem medicamentos totalmente eficazes e uma vacina aprovada para prevenir a doença. Objetivo. Realizar uma revisão literária dos candidatos à vacina contra C. parvum. Método. Revisão documental, mediante pesquisa da literatura dos últimos 20 anos, disponível nas bases de dados PubMed central, WEB OF SCIENCE, Embase, REDALYC e LILACS. Resultados. Vacinas atenuadas, recombinantes e baseadas em DNA, expressas em vetores bacteria- nos e sintéticos, mostraram resultados promissores na indução de imunogenicidade contra antígenos de C. parvum, sendo o antígeno de superfície de 15 kilodaltons de Cryptosporidium parvum (cp15) o antígeno indutor de uma melhor resposta imune celular e humoral no modelo murino estudado. Conclusão. Se espera que a incorporação de novas técnicas para a seleção de antígenos promissores e a execução de um grande número de ensaios in vivo favoreçam o desenvolvimento de uma vacina totalmente eficaz contra C. parvum. Embora o caminho para alcançar este objetivo seja longo e difícil, torna-se a melhor alternativa para controlar uma das doenças de interesse na saúde pública com maior impacto na população imunocomprometida.

Prevención de la infección por Streptococcus del grupo B en gestantes / Prevention of Group B Streptococcal Infection in Pregnant Women / Prevenção da infecção pelo Streptococcus do grupo B as mulheres grávidas: Revisão do tema

Introducción: La infección neonatal por Streptococcus del Grupo B en mujeres gestantes es un problema creciente a nivel mundial y tiene múltiples consecuencias para el recién nacido, su prevención impacta directamente la morbi-mortalidad neonatal. Objetivo: Brindar al lector información relevante sobre la importancia clínica, nuevos métodos de tamizaje y formas de prevención de la infección por Streptococcus del Grupo B en gestantes, que será de utilidad para evitar complicaciones del binomio materno-fetal. Metodología: En esta revisión de la literatura, se estudiaron 53 artículos, abordando evidencia tanto en el ámbito local e internacional, utilizando las bases de datos PubMed, ScienceDirect y Google Scholar, dentro los criterios de búsqueda se tuvo en cuenta el año de publicación, incluyendo artículos que fueron publicados a partir del año 2011. Resultados: La comunidad internacional ha desarrollado guías y planes de prevención; en la actualidad, para una profilaxis y prevención adecuada se proponen diversos métodos, partiendo del tamizaje para las maternas, uso de antibióticos durante el embarazo y parto, además del desarrollo de vacunas maternas para prevenir infecciones. Conclusiones: La colonización por Streptococcus del Grupo B en gestantes y el riesgo que conlleva para el recién nacido y su madre, exige una constante actualización en técnicas de tamizaje, prevención y manejo. Numerosos avances en estos campos vienen llevándose a cabo en los últimos años y su fortalecimiento y desarrollo será clave para impactar positivamente la morbi-mortalidad materno-fetal. [Martínez-Sánchez LM, Restrepo-Arango M, Sánchez-Díaz E, Marín-Cárdenas JS,Gallego-González D,Vélez-Peláez MC. Prevención de la infección por Streptococcus del grupo B en gestantes. MedUNAB 2017; 20(2): 182-189].

Introduction: The neonatal infection by Group B Streptococcus in pregnant women is a growing problem worldwide and has multiple consequences for the newborn, so its prevention directly impacts neonatal morbimortality. Objective: To provide the reader with relevant information about the clinical importance, new screening methods and ways to prevent Group B Streptococcus infection in pregnant women which will be useful to avoid complications in the pairing of maternal-fetal. Methodology: In this review of literature, 53 articles were studied addressing local and international evidence by using PubMed, ScienceDirect and Google Scholar databases; within the search criteria the year of publication was taken into account to do so, thus articles published from 2011 were included. Results: The international community has developed guidelines and prevention plans for this infection. Currently, for an adequate prophylaxis and prevention, various methods are proposed such as the screening for expectant mothers, the use of antibiotics during pregnancy and childbirth, and the development of maternal immunization to prevent infections as well. Conclusions: The colonization by Group B Streptococcus in pregnant women and the risk that this entails to the newborn and his/her mother requires constant updating in techniques for screening, prevention and management of it. Numerous advances in these fields of study have been carried out in recent years, and this strengthening and its development will be the key to impact, in a positive way, the maternal-fetal morbimortality. [Martínez-Sánchez LM, Restrepo-Arango M, Sánchez-Díaz E, Marín-Cárdenas JS,Gallego-González D, Vélez-Peláez MC. Prevention of Group B Streptococcal Infection in Pregnant Women. MedUNAB 2017; 20(2): 182-189].

Introdução: A infecção neonatal pelo Streptococcus do Grupo B em mulheres grávidas é um problema crescente no mundo inteiro e tem múltiplas conseqüências para o recém-nascido. Sua prevenção afeta diretamente a morbidade e mortalidade neonatal. Objetivo: Oferecer ao leitor a informação relevante sobre a importância clínica, os novos métodos de seleção e as formas de prevenir a infecção por Streptococcus do Grupo B em mulheres grávidas, o que será muito útil para evitar as complicações tanto para a mãe quanto para o feto. Metodologia: Nesta revisão da literatura, foram estudados 53 artigos, ressaltando as evidências tanto no nível local como internacional y se utilizaram os bancos de dados em PubMed, ScienceDirect e Google Scholar. Um dos critérios da pesquisa foi verificar o ano da publicação e incluir somente os artigos publicados a partir de 2011. Resultados: Atualmente, a comunidade internacional desenvolveu diretrizes e planos de prevenção para a profilaxia e a prevenção adequada, propondo diversos métodos como: Atriagem materna, o uso de antibióticos durante a gravidez e o parto, além do desenvolvimento das vacinas maternas para preveniras infecções. Conclusões: A colonização por Streptococcus do Grupo B em mulheres grávidas e o risco que isso implica para o recém-nascido e sua mãe, requer uma atualização constante nas técnicas da triagem, da precaução e do tratamento. São numerosos os avanços realizados, nesta área, nos últimos anos. O seu fortalecimento e desenvolvimento são fundamentais para interferir positivamente na doença e na mortalidade materno-fetal. [Martínez-Sánchez LM, Restrepo-Arango M, Sánchez-Díaz E, Marín-Cárdenas JS, Gallego-González D, Vélez-Peláez MC. Prevenção da infecção pelo Streptococcus do grupo B nas mulheres grávidas: Revisão do tema. MedUNAB 2017; 20(2): 182-189].

Research advance in Clostridium difficile vaccine / 中华检验医学杂志

The risk factors of Clostridium difficile infections increased in recent years , such as the underlying disease, hospitalization duration, age, the use of antibiotics, the use of proton pump inhibitors and so on.The rate of Clostridium difficile infection and recurrence are still high despite the appear of new antibiotics such as rifaximin, nitazoxanide, tigecycline, ramoplanin, fidaxomicin, and non-antimicrobial such as drugs toxin neutralizer chamber , biological therapeutic agents , fecal transplantation , systemic antibody method , intravenous immunoglobulin and so on.The vaccine is the most ideal way of prevention and treatment of Clostridium difficile infection.The research in Clostridium difficile vaccine lasted for nearly 20 years.Except the monoclonal antibody vaccine and toxoid vaccine against toxin A and toxin B have achieved better results in the human , some recombinant vaccines against the toxin receptor and the key pathogenic factor of Clostridium difficile also achieved good effect in animal.

Anti-infective immunity of recombinant Bifidobacteria bifidum-Eg95 vaccine of Echinococcus granulosus in mice / 中国地方病学杂志

Objective To investigate the protective immunity in mice immunized with recombinantBifidobacteria bifidum(Bb)-Eg95 vaccine of Echinococcus granulosus (Eg) and challenged with Eg protoscoleces.Methods Fifty-six female BALB/c mice 12-14 weeks old and weighed 20-25 g were vaccinated with the recombinant Bb-Eg95 vaccine subcutaneously,intramuscularly,intranasally and orally,respectively,with blank vector,Bb and medium of solution(MRS) as control,8 mice in each group.Mice were challenged with Eg protoscoleces on week 8 after immunization and killed on week 25 after infection.The weight of hydatid cyst was measured and the decreased larva rate was calculated.Sera were collected to determine the levels of IgE,IgG and its subclasses by enzyme linked immunosorbent assay(ELISA).Splenocytes were collected and cultivated to test the proliferation of splenocytes using methyltetrazolium (MTT) assay under EgAg and concanavalin A (ConA) stimulation.The results were compared with analysis of variance and the comparison between two groups was performed with LSD-t test.Results There was significant difference in the weight of hydatid cyst between groups (F =11.062,P ＜ 0.05).Compared with MRS control group[(0.075 ± 0.019)g],the hydatid cyst weight decreased in subcutaneous group [(0.050 ± 0.013)g],intramuscular group[(0.050 ± 0.019)g],intranasal group[(0.028 ± 0.016)g] and oral group [(0.031 ± 0.018)g,all P ＜ 0.01).Compared with subcutaneous and intramuscular groups,the hydatid cyst weight decreased in intranasal and oral groups(all P ＜ 0.05).The decreased larva rate was inversely proportional to the weight of hydatid cyst.There was significant difference in the levels(obsorbancy,A) of IgG,IgG2a,IgG2b,IgG1,IgG3 and IgE between these groups(F =21.774,36.977,27.071,14.746,10.131,9.444,P ＜ 0.05 or P ＜ 0.01).Compared with MRS control group (0.015 ± 0.002,0.002 ± 0.001,0.003 ± 0.001),the levels of IgG,IgG2a and IgG2b increased in subcutaneous group(0.022 ± 0.004,0.007 ± 0.002,0.008 ± 0.002),intramuscular group (0.023 ± 0.003,0.008 ± 0.002,0.007 ± 0.002),intranasal group(0.032 ± 0.007,0.012 ± 0.002,0.013 ± 0.004)and oral group(0.028 ± 0.006,0.010 ± 0.003,0.010 ± 0.002,P ＜ 0.05 or P ＜ 0.01).Compared with subcutaneous and intramuscular groups,the levels of IgG,IgG2a and IgG2b increased in intranasal and oral groups(P ＜ 0.05 or P ＜ 0.01).Compared with MRS control group(0.009 ± 0.001,0.009 ± 0.002,0.009 ± 0.001),the levels of IgG1,IgG3 and IgE decreased in subcutaneous group(0.022 ± 0.004,0.007 ± 0.002,0.008 0.002),intramuscular group(0.004 ± 0.001,0.004 ± 0.001,0.004 ± 0.002),intranasal group(0.005 ± 0.002,0.005 ± 0.003,0.005 ± 0.002)and oral group(0.005 ± 0.001,0.004 ± 0.002,0.004 ± 0.003,all P ＜ 0.01).There was significant difference in the proliferation of splenocytes in the supernatant of cultured splenocyte,of cultured splenocyte + EgAg and of cultured splenocyte + ConA(F =63.975,359.833,167.399,P ＜ 0.01).There was significant difference in the proliferation of splenocytes inside groups(F =6741.955,4953.667,869.320,201.235,175.413,139.653,169.994,all P ＜0.01).Compared with the cultured splenocyte the proliferation of splenocytes increased in the cultured splenocyte +EgAg and splenocyte + ConA (all P ＜ 0.01).Compared with the cultured splenocyte + EgAg,the proliferation of splenocytes increased in the cultured splenocyte + ConA(P ＜ 0.01).Conclusion An effective and protective immunity is induced by the recombinant Bb-Eg95 vaccine of Eg in mice.

Construction of a recombinant BCG secreting BP26 and the effects of BP26 on CD4+ and CD8+ T cells in mice / 中国地方病学杂志

Objective To develop a BP26 recombinant BCG (rBCG-BP26) vaccine,and to observe the effects of rBCG-BP26 on CD4+,CD8+ T cells in immunized mice.Methods The recombinant shuttle vector pMV261-Ag85B-BP26 was constructed by using traditional molecular biological technology.The recombinant strains were obtained by kanamycin resistance screening and PCR identification after electroporation.Western blotting was used to detect the expression of recombinant BP26 vaccine in immunized mice.Safety experiment was carried out in three different groups:the target experiment(rBCG-BP26) group,the positive control(BCG) group and the negative control(PBS) group,15 BALB/c mice in each group.Intradermal inoculations of 100 μl rBCG-BP26 [containing 106 colony forming units(CFU)],BCG,and PBS were carried out,respectively.Signs of mice in each group were observed.After immunization for 10,20,30,and 40 days,body weight was weighed,and tail blood was collected to observe the change of peripheral blood CD4+ and CD8+ T cells by flow cytometry.Results The rBCG-BP26 was successfully constructed.The expression of BP26 protein was detected in the liquid medium and the bacteria cells.The results of safety test analysis showed that there were no significant differences in signs and body weights(F=2.468,0.331,1.520,0.739,all P＞ 0.05),between PBS group[ (19.24 ± 0.54),(21.37 ± 0.66),(22.83 ± 0.62),(25.06 ± 0.37)g],BCG group[ (19.90 ± 0.02),(21.53 ± 1.57),(21.95 ± 0.55),(24.70 ± 0.39)g]and rBCG-BP26 group[ (19.16 ± 0.55 ),(20.89 ± 0.20),(22.15 ± 0.76),(24.60 ± 0.64)g].The results of flow cytometry showed that the percentages of CD4+ T cell level were lower in BCG group(26.70％,33.07％) and rBCG-BP26 group( 13.40％,26.70％) than that of the PBS group(33.85％,29.33％) and the values of CD4+/CD8+ T cells increased in rBCG-BP26 group (0.69％,1.27％,1.57％,1.70％ ) 10,20 and 30 days after immunization.Conclusions Recombinant BCG-BP26 vaccine strain can express brucella BP26 protein efficiently.Furthermore,its virulence is mild,and it can activate CD4+,CD8+ T cells in the body.It can be used as one of candidate vaccine strain against brucellosis.

Induction of cytotoxic T lymphocytes against cervical cancer cell line CaSki using therapeutic dendritic cell vaccine / 肿瘤

Objective: To observe the inductive effect of cytotoxic T lymphocytes (CTLs) against human cervical cancer cell line CaSki using therapeutic dendritic cells (DCs) vaccine in vitro . Methods:. Immature mouse DCs were isolated and cultured. The expressions of cell-surface CD40, CD86, major histocompatibility complex (MHC)-. and CD11c in immature DCs were detected by flow cytometry (FCM). Then the immature mouse DCs were infected with recombinant adenoviral vector carrying human papillomavirus (HPV )16 E 6/E 7 (pAd-E6/E7), and the CaSki cell lysate-loaded autologous DCs vaccine was prepared. The expression of green fluorescent protein in pAd-E6/E7-infected immature mouse DCs was observed under a laser scanning confocal microscope, and the expression of E6 protein was detected by Western blotting. DCs vaccine was used to induce specific CTLs, were subsequently co-cultured with CaSki cells. The killing effect of CTLs against CaSki cells was determined using cell counting kit8(CCK8) assay. Results: HPV16 E6/E7-specific DCs vaccine was successfully prepared. CTLs which induced by DCs vaccine exerted a killing effect on CaSki cells. This killing effect was higher in pAd-E6/E7-infected group than those in CaSki cell lysate-loaded group and the untreated control group (P<0.05). Conclusion: Genetically modified DC vaccine can successfully be prepared by infection with pAd-E6/E7, and it has a significant effect on triggering of specific CTLs against CaSki cells.

Construction and expression of the recombinant plasmid pET28α-Sj26GST-Sj32 of Schistosoma japonicum in Escherichia coli BL21(DE3) / 中国地方病学杂志

Objective To construct and express the recombinant plasmid pET28α-Sj26GST-Sj32 of Schistosoma japonicum(Sj) in Escherichia coli BL21 (DE3). Methods Total RNA was extracted from Sj adult worms by ultrasound-breaking, Sj26GST and Sj32 antigen gene was respectively amplified by RT-PCR from the total RNA; Sj26GST-Sj32 fusion gene obtained with gene splicing by overlap extension(SOEing) was cloned into prokaryotic expression plasmid pET28α and transformed into Escherichia coli BL2 (DE3) to construct pET28α-Sj26GST-Sj32;BL21 (pET28α-Sj26GST-Sj32) was induced with isopropyl-β-D-thiogalactopyranosid (IPTG), and the expressed products were analyzed and identified by sodium dodecyl sulfate polyacrylamide gel electropheresis (SDS-PAGE)and Western blotting. Results The 1991 bp Sj26GST-Sj32 fusion gene was successfully amplified by gene SOEing and cloned into pET28α by restriction analysis and PCR identification, the recombinant plasmid pET28α-Sj26GST-Sj32 was successfully constructed; the relative molecular mass of the expressed recombinant protein was approximately 69 × 103 by SDS-PAGE, and the amount of the expressed protein was 25% of the total bacterial proteins; the fusion protein could be recognized by sera from rabbits infected with Sj by Western blotting.Conclusions The recombinant plasmid pET28α-Sj26GST-Sj32 is successfully constructed and highly expressed in Escherichia coli in fused form with His-tag, and the expressed fusion protein shows specific antigenicity.

Construction and expression of the recombinant plasmid pET32α-Sj26GST of Schistosoma japonicum in Escherichia coli BL21(DE3) / 中国地方病学杂志

Objective To construct and express the recombinant plasmid pET32α-Sj26GST of Schistosoma japonicum(sj)in Escherichia coli(E.coli)B121(DE3).Methods The total RNA was extracted from sj adult worms by ultrasound-breaking,Sj26GST antigen gene was amplified by RT-PCR from the total RNA,then cloned into prokaryotic expression plasmid pET32α(+) and transformed into E.coli B12(DE3)to construct pET32α-Sj26GST;BL21(pET32α-Sj26GST)WaS induced with isopropyl-β-D-thiogalactopyranosid(IPTG),and the expressed products were analyzed and identified by SDS-PAGE and Western blot.Results The 676 bp Sj26GST gene was successfully amplified by RT-PCR and cloned into pET32α(+)by restriction analysis and PCR identification,the recombinant plasmid pET32α-Sj26GST was successfully constructed;the relative molecular mass of the expressed recombinant protein was approximately 49×103 by SDS-PAGE,and the amount of the expressed protein was 24%of the total bacterial proteins;the fusion protein could be recognized by sera from rabbits infected with sj by Western blot.Conclusions The recombinant plasmid pET32α-Sj26GST is successfully constructed and highly expressed in E.coli in fused form with Trx-tag and His-tag,and the expressed fusion protein shows specific antigenicity.

Dynamic observation on cytokines of splenocytes in mice immunized with recombinant Bb-Eg95-EgA31 vaccine of Echinococcus granulosus / 中国地方病学杂志

Objective To dynamically observe the changes of cytokines of splenocytes in mice immunized with recombinant bifidobacteria bifidum (Bb)- Eg95-EgA31 vaccine of Echinococcus grauulosus (Eg). Methods Balb/c mice were vaccinated by 5× 108 colony forming unit(CFU) orally and 5 × 105 CFU intranasally, respectively.Mice were killed on week 0,2,4,6,8,10, 12,14,16, 18 and 20 after immunization, respectively, and spleens were separated for cell culture with the stimulation of EgAg, concanavalin A (ConA) or lipopolysaccharide (LPS). The splenocyte supernatants were collected to determine the levels of interferonγ(IFN-γ), interleukin(IL)-12, tumor necrosis factor α(TNF-o) and IL-l0 using enzyme linked immunosorbent assay(ELISA) with MRS as control. Results In the oral immunization group, the levels of IFN-γ, IL-12, TNF-α and IL-10 showed a significant increase from week 2 to week 8, week 2 to week 8, week 4 and week 6 to week 10 after vaccination, respectively, and reached the highest level on week 4, week 2, week 4 and week 6 after vaccination, respectively;in EgAg stimulation group, the levels of IFN-γ, IL-12, TNF-α and IL-10 were (700.0 ± 115.5), (45.0 ± 5.8), (350.0 ± 57.7), (112.5 ± 14.4)ng/L, respectively, compared with week 0[(35.0 ± 5.8), (12.5 ± 2.9), (190.0 ± 11.6), (25.0 ± 5.8)ng/L, P ＜0.05 or ＜ 0.01] and MRS control group[(37.5 ± 5.0),(13.8 ± 2.5), (195.0 ± 5.8), (27.5 ± 2.9)ng/L, P＜ 0.05or ＜ 0.01]. In the intranasal immunization group, the levels of IFN-γ, IL-12, TNF-α and IL-10 showed an obvious increase from week 2 to week 8, week 2 to week 8, week 2 to week 6 and week 6 to week 16 after vaccination,respectively, and reached the highest level on week 2, week 2, week 4 and week 8 after vaccination, respectively;in EgAg stimulation group, the levels of IFN-γ, IL-12, TNF-α and IL-10 were (700.0 ± 115.5), (55.0 ± 5.8),(275.0 ± 28.9), (140.0 ± 11.6)ng/L, compared with week 0[(35.0 ± 5.8), (12.5 ± 2.9), (190.0 ± 11.6), (25.0 ±5.8)ng/L, P ＜ 0.05 or ＜ 0.01] and MRS control group[(37.5 ± 5.0), (13.8 ± 2.5), (195.0 ± 5.8), (27.5 ± 2.9)ng/L, P ＜ 0.05 or ＜ 0.01]. The cytokine levels in the groups with EgAg, ConA or LPS stimulus were significantly higher than those in the corresponding splenocytes suspension groups(P ＜ 0.05 or ＜ 0.01) , and the cytokine levels in the groups with ConA or LPS stimulus were obviously higher than those in the corresponding groups with EgAg stimulation(P ＜ 0.05 or ＜ 0.01). Conclusion The mixed Th1 and Th2 type response can be induced in mice immunized with the recombinant Bb-Eg95-EgA31 vaccine of Echinococcus granulosus in the early stage of immunization(2 to 6weeks).

Construction and identification of recombinant Bb-Eg95 vaccine of Echinococcus granulosus / 中国地方病学杂志

Objective To construct and identify recombinant Bifutobacteria (rBb)-Eg95 vaccine of Echinococcus granulosus (Eg). Methods The total RNA was extracted from hydatid cyst protoscoleces shattered by ultrasound, Eg95 antigen encoding gene was obtained by reverse transcription-polymerase chain reaction(RT-PCR) from the template of total RNA using the primer designed according to the DNA sequence of Eg95, the gene was cloned into Escherichia coli-Bifutobacteria(E.coli-Bb) shuttle plasmid pGEX-1λT and transformed into E.coli BL2 (DE3) competent cell to construct recombinant plasmid pGEX-Eg95 using BamH Ⅰ and EcoR Ⅰ, the recombinant plasmid was identified by restriction endonuclease digestion, then was electroporated into Bb to construct rBb-Eg95 vaccine, the vaccine was identified by PCR. Results Four hundred and seventy-one bp Eg95 gene was amplified by RT-PCR, the products of restriction endonuclease digestion were the same as expected(471 bp Eg95 gene and 4947 bp pGEX-1λT), 471 bp Eg95 gene fragment was amplified by PCR from the template of pGEX-Eg95 extracted from rBb vaccine. Conclusion rBb-Eg95 vaccine of Eg is successfully constructed, which lays the theoretical foundation for exploitation and utilization of this vaccine.

Dynamic observation on subsets of splenocytes in mice by immunization with recombinant BCG-Eg95 vaccine of Echinococcus granulosus / 中国地方病学杂志

Objective To dynamically observe the changes of subsets of splenocytes in mice by immunization with recombinant BCG-Eg95 vaccine of Echinococcus granulosus(Eg).Methods Balb/c mice were divided randomly into 3 groups according to their weishts:intranasal group.per os group and PBS control.The mice were vaccinated intranasally or orally by the vaccine respectively in experimental groups.and the control mice were given phosphate buffer saline intranasally.These mice were killed to get spleen on 0,2,4,6,8,10,12, 14,16 and 18 week of immunization,respectively.Splenocytes were separated to measure subsets of CD4+ and CD8+T ceUs by FACsort.Results There were marked differences in ratio of CD4+ and CD8+ subsets among the different groups(F value were 21.56 and 22.08 respectively,P＜0.05).There were very marked differences in ratio of CD4+ and CD8+ subsets in different weeks(F value were 5.75 and 6.29 respectively.P＜0.01).In the intranasal group,CD4+ and CD8+ T subsets increased obviously in 6～18 weeks and 12 weeks,and reached the highest level on 10 and 12 week,espectively.Their values were 0.348±0.013 and 0.090±0.003.respectively.There were marked or very marked differences(q value were 7.32 and 5.32 respectively,P＜0.01 or＜0.05)in comparison with 0 week(0.230±0.022 and 0.069±0.015).In the oral group,CD4+and CD8+ subsets rose reinarkablv on 6-16 weeks and 8-18 weeks,achieved the hishest level on 10 and 16 weeks,respectively.Their vahes were 0.405± 0.006 and 0.096±0.004,respectively.There were marked or very marked difference(q value were 7.53 and 5.35 respectively,P＜0.01 or＜0.05)in comparison with week 0(0.230±0.022 and 0.069±0.015).Conclusion CD4+and CD8+T subsets may play an important role in immune response induced in mice by rBCG-Eg95 vaccine.

Comportamiento reactogénico de la vacuna cubana contra la hepatitis B en niños física y mentalmente discapacitados

Se estudió la reactogenicidad de la vacuna recombinante cubana contra el virus de la hepatitis B, derivada de células de levadura (Heberbiovac-HB), al aplicar dosis de 5 y 10 mg y emplear el esquema de inmunización 0, una segunda dosis al mes y la tercera a los 6 meses a 2 grupos de niños física y mentalmente discapacitados de 5 a 14 años de edad. Los síntomas observados en el total de la población estudiada fueron de 5,1 %, mientras que en los grupos vacunados con 10 y 5 mg, la sintomatología fue de 4,8 y 5,4 % respectivamente; sin que se encontraran diferencias significativas en los síntomas postvacunales entre los grupos de estudio. El signo predominante fue la febrícula con el 84,9 % de las observaciones positivas encontradas. En nuestro estudio se constató la baja reactogenicidad de la vacuna Heberbiovac-HB, lo que la hizo segura y recomendable para la protección contra el virus de la hepatitis B en los grupos de niños impedidos físicos y mentales estudiados.

The reactogenecity of the Cuban recombinant yeast-derived hepatitis B vaccine (Heberbiovac-HB) was studied on administering doses of 5 and 10 mg and using the immunization scheme 0 in 2 groups of physical and mentally disabled children aged 5-14. The second dose was given at a month and the third one at 6 months. The symptoms observed in the whole population under study were 5,1 %, whereas in the groups vaccinated with 5 and 10 mg, the symptomatology was 4,8 and 5,4 %, respectively. No significant differences were observed in the postvaccinal symptoms between the studied groups. The predominant sign was low-grade fever with 84,9 % of the positive observations found. In our study, it was confirmed the low reactogenecity of the Heberbiovac-HB vaccine, which makes it safe and recommendable for the protection against the hepatitis B virus in the groups of physical and mentally disabled children that were studied.

Seguridad e inmunogenicidad de la vacuna cubana heberbiovac hb en poblaciones de América, Europa, África y Asia

Se evaluaron la reactogenicidad e inmunogenicidad de la vacuna cubana antihepatitis B (Heberbiovac HB) en 2 942 adultos y 804 niños de diferentes países pertenecientes a 3 continentes con el empleo de esta vacuna con 3 dosis, diferentes esquemas y vías de inoculación. Sólo se encontró dolor e induración local entre 15 a 25 % de los vacunados. La seroprotección se comportó como sigue: a los 60 d después de iniciado el esquema, con sólo 2 dosis, fue de 98 % en niños y 82 % en adultos; 75 d después de finalizado el esquema estuvo entre 92 y 100 %; al año se mantenía con seroprotección más de 96 % de los adultos cuando se usó la vía intramuscular, y después de transcurridos 2 años de terminada la vacunación se encontró 100 % de seroprotección en niños y adultos e hiperrespuesta de 79 y 71%, respectivamente. La vacuna Heberbiovac HB tiene gran inmunogenicidad con muy corta latencia, intensidad superior a otras vacunas de origen plasmático y recombinante, y gran durabilidad. Esta vacuna tuvo un efecto booster manifiesto en los que tuvieron hiporrespuesta a otras vacunas contra hepatitis B, pues 15 d después del inóculo, 75 % tuvo cifras de anticuerpos protectoras en el suero.

Reactogenecity and immunogenicity of the Cuban anti-HBV vaccine called Herberbiovac HB were evaluated in 2 942 adults and 804 children from a number of countries in 3 continents by using 3 doses of this vaccine with different innoculation schedules and routes of administration. Only pain and local induration were found in 15 to 25% of the vaccinated people. Seroprotection was as follows: 98% in children and 82% in adults , with only two doses of vaccination 60 days after the starting of the schedule; 92% and 100% respectively 75 days after the completion of the vaccination program; over 96% in adults after one year when the IM administration was used. After 2 years of finishing the vaccination, seroprotection reached 100% in children and adults alike with a hyperesponse of 79% and 71% respectively. The vaccine Heberbiovac HB shows high immunogenicity with very short latency, intensity higher than other plasmatic and recombinant vaccines and great durability. This vaccine had an booster effect on those individuals showing hyperesponse to other anti-HB vaccines because 15 days after the innoculation, 75% of vaccinated persons had protective antibodies in their sera.

Inmunogenicidad de la vacuna cubana recombinante heberbiovac HB en modelos experimentales y aplicados al humano

Uno de los pilares fundamentales en el control, la eliminación y posible erradicación de la hepatitis viral tipo B-D es la utilización de la vacuna de producción cubana contra la hepatitis B. Se desarrollaron modelos experimentales y aplicados al humano que permitieron el estudio de inmunogenicidad mediante distintas vías, dosis y esquemas. Se trabajó experimentalmente se trabajó con ratones BALB/c, con la aplicación de 1 mg/dosis por vía intramuscular (IM) e intraperitoneal (IP) en 3 esquemas diferentes 0-1-2, 0-1-4 y 0-4-8 semanas. La inmunogenicidad se estudió mediante la cuantificación del anticuerpo contra el antígeno de superficie (AgsHB), con la aplicación de un método inmunoenzimático. En todos los animales hubo seroconversión con los esquemas 0-1-4 y 0-4-8 semanas. En el esquema 0-1-2 la vía IP resultó más inmunogénica que la vía IM, produjeron 60 y 35 % de seroconversión, respectivamente. La vía IP tuvo un coeficiente de variación menor cuando se compararon los esquemas 0-1-4 y 0-4-8 semanas, de todas formas resultó alto para ser animales BALB/c. En humanos se inmunizaron estudiantes de medicina y enfermería con el empleo de 20 mg/dosis por vía IM y 2 mg/dosis vía intradérmica (ID), con los esquemas 0-1-4 y 0-4-8 semanas; se demostró que la seroprotección e hiperrespuesta era mayor en el esquema 0-4-8 independientemente de la vía utilizada y que el esquema 0-1-4 no produjo la inmunogenicidad requerida por lo que debe ser utilizado de manera excepcional. Se obtuvieron estándares de anticuerpos nacionales para la aplicación en métodos de cuantificación de anti-AgsHB, tanto en estudios experimentales como en humanos.

One of the fundamental pillars in the control, elimination and possible eradication of B-D viral hepatitis is the use of the Cuban-made hepatitis B vaccine. Experimental models as well as models for humans were developed to study immunogenicity using various routes of administration, doses and schedules. Balb/c mice were used on experimental basis to which 1 mg/dose were administered by intramuscular(IM) and intraperitoneal (IP) within three different vaccination schedules, i,e, at 0, 1, and 2 weeks; 0, 1 and 4 weeks, and 0, 4 and 8 weeks. Immunogenicity was stufied through quantification of antibodies to surface antigens by using an immunoenzymatic method. Seroconversion was present in all animals at 0, 1 and 4 and 0, 1, and 8 weeks schedule. However, in 0, 1 and 2 schedule, IP route of administration was more immunogenic than IM, with 60% and 35% seroconversion respectively. IP route had a lower variation coefficient than 0, 1 and 4 week and 0, 4 and 8 schedules were compared, but anyway, it was high even for Balb/c animals. Medical and nursing students were immunized with 20 mg/dose IM and 2mg/dose intradermally within 0, 1 and 4 week and 0,4 and 8 w schedules. It was showed that seroprotection and hyperesponse were greater in 0, 4 and 8 week vaccination schemes regardless of the route of administration and that 0, 1 and 4 w schedule does not bring required immunogenicity, therefore, it should be used exceptionally. National antibody standards were obtained to be applied in anti-HbsAg quantification methods both in experimental and human-based studies.

Inmunogenicidad de la vacuna recombinante cubana contra la hepatitis B en trabajadores de la salud peruanos

Se investigó la inmunogenicidad (seroconversión, seroprotección, hiperrespuesta y media geométrica) producida por la vacuna recombinante cubana contra la hepatitis viral tipo B en Cuba, en un estudio multicéntrico nacional, concurrente. Se aplicó el esquema de 0-1-2meses en 211 trabajadores de la salud, susceptibles, pertenecientes al Instituto Peruano de Seguridad Social. La cuantificación del anti-AgsHB se realizó por el método inmunoenzimático de Organon Teknika. Se obtuvo 97 % de seroprotección en sólo 75 d de haber iniciado el esquema, se observó una mayor inmunogenicidad en mujeres menores de 40 años. Se recomienda la aplicación de este esquema como parte del programa de control en la hepatitis viral tipo B por su simetría, corta latencia y grado de protección.

We researched into the immunogenicity (seroconversion, hyperesponse and geometric mean) caused by the Cuban recombinant anti-B viral hepatitis in Cuba in a national concurrent multicenter study. The 0, 1 and 2 month immunization schedule was used in 211 sensitive health workers who worked for the Peruvian Institute of Social Security. The immunoenzymatic method called Organon Teknika. 97% seroprotection was reached just in 75 days after the vaccination schedule started; higher immunogenicity was observed in under 40 years-old women. We recommended the implementation of this schedule as part of the control program of B hepatitis because of its simetry, short latency and level of protection.

Durabilidad de la respuesta inmune contra el vhb en niños de un círculo infantil en Cuba

El Ministerio de Salud Pública de Cuba se ha propuesto la eliminación para el año 2000 de la hepatitis viral tipo B. Para cumplir este objetivo lleva a cabo un Programa Nacional que comenzó en 1991 con la vacunación de los niños nacidos de madres portadoras de hepatitis B y posteriormente se amplió a todos los recién nacidos a partir de 1992. Uno de los parámetros para evaluar la inmunogenicidad de una vacuna es la durabilidad de la respuesta posvacunal, que permite demostrar, además, la necesidad o no de una dosis refuerzo. Tomando en consideración la importancia de este tipo de estudio se realizó la cuantificación de los niveles de anticuerpos contra el VHB (anti-AgsHB) en niños pertenecientes a un círculo infantil, vacunados según el Programa Nacional de Vacunación. Éstos estaban distribuidos por años de vida: primer año (I): 19 niños, segundo año (II): 10, tercer año (III): 31, cuarto año (IV): 24, y en el quinto año (V): 22, para un total de 106 niños. Las muestras serológicas se evaluaron mediante el método inmunoenzimático ELISA, en el Departamento de Inmunología del Instituto de Ciencias Básicas y Preclínicas "Victoria de Girón" (ICBP). En cada grupo estudiado se determinó la proporción de niños con seroprotección (I0 Ul/L o más) e hiperrespuesta (100 Ul/L o más). Se calculó además la media aritmética. Los niveles de seroprotección e hiperrespuesta fueron superiores a 93 y 76 %, respectivamente. La media aritmética (X) estuvo por encima de 181 Ul/L en todos los grupos estudiados.

The Ministry of Public Health of Cuba sets out to wipe out viral hepatitis B for the year 2000. To attain this goal, it implemented a National Program which started in 1991 with the immunization of children from Hepatitis B carrier mothers and was extended to all neonates from 1992 on. One of the parameters to evaluate immunogenicity of a vaccine is durability of post-vaccine response that permits to prove whether a reinforcement dose is needed or not. Taking the importance of this type of study into account, the levels of antibodies to HBV (anti-HbsAg) were quantified in the children of a day-care center who were vaccinated as part of the National Immunization Program. These children were distributed by years of life: First year(I), 19 children; second year (II) 10; third year (III) 31; fourth year (IV) 24; and firth year (V) 22, totalling 106 children. The serological samples were assessed by ELISA in the Department of Immunology of the "Victoria de Girón" Institute of Basic and Pre-clinical Sciences. In each studied group, the number of children with seroprotection (10 UI/L or higher) and hyperesponse (100 UI/L or higher) were determined. Additionally, the arithmetic mean was calculated. The levels of seroprotection and hyperesponse were over 93 and 76% respectively. The arithmetic mean was over 181 UI/L in all the studied groups.

Efectividad absoluta y relativa de la vacunación antihepatitis B en niños de Quillabamba, Perú, 1997-1999

Conociendo la importancia que la Organización Panamericana de la Salud le concede a la hepatitis B como problema de salud en algunas regiones de América del Sur y atendiendo a las recomendaciones de la comisión responsable del control de este tipo de hepatitis en el Perú, el Ministerio de Salud de este país inició en 1996, la vacunación de menores de 1 año en áreas de alta e intermedia endemicidad. En este trabajo se realizó un estudio concurrente de 115 niños inmunizados con la vacuna Heberbiovac HB (10 µg/dosis, 0-2-4 meses) integrada al Programa Ampliado de Inmunizaciones en Perú y 77 niños no vacunados. A todos se les realizó estudio serológico para conocer prevalencia de infección y de portadores del VHB ( AgsHB y anti-AgcHB) y cuantificación del anti-AgsHB, con el uso de métodos inmunoenzimáticos de la Organon Teknika. En ninguno de los niños vacunados existió evidencia de infección por el virus B, para una efectividad de 100 %. Los porcentajes de seroconversión, seroprotección e hiperrespuesta entre los vacunados fueron de 99,1, 98,3 y 42,6 respectivamente. Entre los no vacunados se encontraron marcadores de infección anterior en 31,1 % y 3,9 % fue positivo al AgsHB. Teniendo en cuenta la edad promedio de aparición de los marcadores y los niveles del AgsHB se pudo pensar que predominaba un patrón de trasmisión horizontal que ameritaba el estudio de conviventes y la evaluación de vías inaparentes de infección. A partir del impacto obtenido con la vacunación, se recomendó vacunar a todos los niños que lo necesitaban aunque se encontraran fuera del rango de edad establecido por el Programa Ampliado de Inmunización, así como a los conviventes donde se demostró circulación viral.

Knowing the importance that the Pan-American Health Organization gives to Hepatitis B as a health problem in some regions of South America and bearing in mind the recommendations of the commission in charge of the control of this hepatitis in Peru, the Ministry of Health in this country started a mass vaccination of under one year-old infants in highly and medium endemic areas. This paper sets forth a concurrent study of 115 children immunized with Heberbiovac HB (10 µg/dose, at 0, 2 and 4 months) which incorporated the Extended Immunization Program in Peru and 77 non-vaccinated children. All of them were serologically analyzed to find out prevalence of infection and of HBV carriers (HbsAg and anti-HbcAg) and their anti-HbsAG was quantified using immunoenzymatic methods of Organon Teknika. There was no evidence of virus B infection in the children accounting for 100 % effectiveness. The percentages of seroconversion, seroprotection and hyperesponse among the immunized children were 99.1, 98.3 and 42.6 respectively. Markers of previous infection were found in 31.1 % of children and 3.9 were HbsAg positive. Considering the average age at which markers occur and the levels of HbsAg, it was thought that a pattern of horizontal transmission predominates, which supports the study of people living in the same place as the infested subject and the assessment of non-evident route of infection. On the basis of the impact of vaccination, it was recommended to immunize all children in need of, even if they are not included in the age range set for the Extended Immunization Program as well as to people living with these children if viral spread is detected.

Inmunogenicidad de la vacuna Heberbiovac-HB en niños

Se aplicó la vacuna recombinante cubana contra el virus de la hepatitis B, con dosis de 10 myg a niños menores de 15 años en esquema de 0,1 y 6 meses. La inmunogenicidad evaluada a los 2, 7 y 12 meses mostró 100,0 % de seroconversión con títulos protectores. El 65,9; 100,0 y 83,5 % de los vacunados alcanzaron títulos mayores de 100 UI/L a los 60, 210 y 360 días. La media geométrica fue 213,6; 8208,2 y 568,0 UI/L, respectivamente, todos los grupos alcanzan 100 % de seroconversión; no obstante, se encuentran diferencias significativas (p < 0,05) a favor de preescolares y escolares respecto a los mayores de 10 años en cuanto al nivel de respuesta (títulos mayores de 100 UI/L) y media geométrica de títulos de anticuerpos en las 3 muestras. Se comprobó el alto poder inmunogénico de la vacuna en estas edades, que la hace recomendable para la protección contra el virus de la hepatitis B (VHB).

The Cuban recombinant vaccine against heaptitis B virus was applied with doses of 10 ìg to children under 15 in a scheme from 0, 1 to 6 months. The immunogenecity was evaluated at 2, 7, and 12 months and showed 100 % of seroconversion with protective titres. 65.9, 100, and 83.5 % of the vaccinated attained titres higher that 100 UI/L at 60, 210, and 360 days. The geometrical mean was of 213.6, 8208.2, and 568.0 UI/L, respectively. All the groups obtained 100 % of seroconversion; however, there were significant differences (p < 0.05) in favor of the preschool and school children compared with those over 10 as regards the response level (titres higher than 100 UI/L) and the geometrical mean of antibody titres in the 3 samples. It was demonstrated the high immunogenic power of the vaccine at these ages, which makes it recommendable for their protection against the hepatitis B virus (HBV).

Inmunogenicidad de la vacuna Heberbiovac-HB en ancianos

Se le aplicó la vacuna recombinante cubana contra el virus de la hepatitis B Herberbiovac HB a un grupo de individuos mayores de 65 a pertenecientes a un hogar de ancianos de Ciudad de La Habana, a la dosis de 20 myg, con el esquema 0, 1 y 6 meses, para estudiar su inmunogenicidad, la cual fue evaluada a los 2, 7 y 12 meses después de aplicada la primera dosis,. A los 60 d se obtuvo 47,1 % de títulos protectores y media geométrica de 6,04 UI/L. Cuando se evaluó la respuesta inmune a los 7 meses se logró 100,0 % de seroconversión (1 UI/L) y seroprotección ( 10 UI/L) y media geométrica de 136,93 UI/L. Finalmente, al año, la seroconversión y la seroprotección también fueron del 100 %, y la media geomètrica de 204,61 UI/L. Se demostrò el alto poder inmunogénico de esta vacuna, lo que la hace recomendable para su uso en la protección contra el virus de la hepatitis B, en este grupo de edad.

The Cuban recombinant vaccine against the hepatitis B virus was applied to a group of individuals over 65 from a geriatric home in Havana City. Dose of 20 ìg were administered within a scheme from 0.1 to 6 months in order to study its immunogenecity, which was evaluated at 2,7, and 12 months after the first dose. 47.1 % of protective titres and geometrical mean of 6.04 UI/L were obtained after 60 days. 100 % of seroconversion ( UI/L) and seroprotection (10 UI/L) and geometric mean of 136.93 UI/L were obtained when the immune response was evaluated on the 7th month. Finally, after a year, seroconversion and seroprotection were also of 100 %, and the geometric mean was of 204.61 UI/L. It was proved the high immunogenic power of this vaccine, which makes it recommendable to protect this age group from the hepatitis B virus.

Use of high-level HBV replication transgenic mice for evaluating drugs treating hepatitis B virus / 中国病理生理杂志

AIM:To study the high-level HBV replication transgenic mice for evaluation of drugs treating hepatitis B virus.METHODS:The HBV transgenic mice were treated respectively with lamivudine,large dose recombinant hepatitis B protein vaccine,?-1b interferon,siRNA to evaluate their pharmacodynamics and mechanism of action.RESULTS:HBV DNA titre was reduced significantly in transgenic mice which were treated with lamivudine(100 mg?kg-1?d-1),recombinant hepatitis B protein vaccine(HBsAg 6 ?g/mouse),?-1b interferon(50 ?g /mouse),respectively.Recombinant hepatitis B protein vaccine and ?-1b interferon promoted the level of IL-2 and IFN-? and increased the Elispot number of spleen cells secreting IFN-? in the treated transgenic mice.HBV transgenic mice were treated with RNAi expression vector pU6-siHBV against HBV through vena caudalis by hydrodynamics technique.Five days later,the level of serum HBsAg was reduced by 56.7% and the inhibition lasted at least 14 days.The HbcAg(+)cells were decreased obviously by immunohistochemistry detection in liver tissue,but the RNAi did not reduce the serum HBV DNA titre.CONCLUSION:These inbreeding high-level HBV replication transgenic mice are reliable and feasible for evaluating the anti-HBV drugs and have its economical and convenient superiority.